Loading...
•
Sep 30, 2020
Boston Scientific Q3 2020 Earnings Report
Generated sales of $2.659 billion, representing a decline of (1.8) percent on a reported basis.
Key Takeaways
Boston Scientific reported Q3 2020 sales of $2.659 billion, a decline of 1.8% on a reported basis compared to the prior year. The company experienced a GAAP net loss of $(169) million or $(0.12) per share, while achieving an adjusted EPS of $0.37.
Sales declined by (1.8)% on a reported basis, (2.5)% on an operational basis, and (5.7)% on an organic basis compared to the prior year period.
GAAP net loss available to common stockholders was $(0.12) per share, while adjusted EPS reached $0.37.
Third quarter sales declined in each reportable segment compared to the prior year period.
FDA approval received for the AVVIGO Guidance System and high bleeding risk indication for SYNERGY and SYNERGY XD Bioabsorbable Polymer Drug-Eluting Stent Systems.
Boston Scientific
Boston Scientific
Boston Scientific Revenue by Segment
Boston Scientific Revenue by Geographic Location
Revenue by Segment
MedSurg Revenue
CapyFin.comCardiovascular Revenue
CapyFin.comRevenue by Geographic Location
Latin America & Canada Revenue
CapyFin.com Forward Guidance
The company had not provided third quarter sales and EPS guidance due to ongoing uncertainty associated with the scope and duration of the COVID-19 pandemic.
Revenue & Expenses
Visualization of income flow from segment revenue to net income